Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 11/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962503 | 1.00 | CHRM3 (0.57) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL4353701 | 1.00 | CHRM3 (0.57) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL5425075 | 1.00 | CHRM3 (0.57) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL962504 | 1.00 | CHRM3 (0.57) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL5352925 | 1.00 | CHRM3 (0.57) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL13590337 | 0.95 | CHRM3 (0.61) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL13590293 | 0.95 | CHRM3 (0.61) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL13590478 | 0.95 | CHRM3 (0.61) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL13590079 | 0.95 | CHRM3 (0.61) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL13590341 | 0.95 | CHRM3 (0.61) | CHRM3KCNH2ADRB2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638639-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7615566-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351718-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351717-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-04-05 | — | — | US | disclosed |
| US-7183292-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1633707-A1 | 1- (ALKYLAMINOALKYL-PYROLIDIN-/PIPERIDINYL) -2, 2-DIPHENYLACETAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005003090-A1 | 1- (ALKYLAMINOALKYL-PYROLIDIN-/PIPERIDINYL) -2, 2-DIPHENYLACETAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | CHRM3 4/4885KCNH2 578/4885ADRB2 24/4885 |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | CHRM3 4/4885KCNH2 578/4885ADRB2 24/4885 |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, ADRA1D | CHRM3 16/4885KCNH2 593/4885ADRB2 19/4885 |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | CHRM3 4/4885KCNH2 578/4885ADRB2 24/4885 |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | CHRM3 4/4885KCNH2 578/4885ADRB2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.